$4.48
+0.67%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$4.48
From 52W high−53.04%
Volume4.22M
Market cap$1.57B
P/E (TTM)—
P/S (TTM)9.3x
Div yield—
Key dataOct 19, 2026
Open
$4.48
From 52W high
−53.04%
Volume
4.22M
Market cap
$1.57B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−9.2x
P/E (TTM)
—
RSI (14)
23.5
MomentumView details →
1D Return
+0.67%
YTD Return
−50.95%
SummaryUpdated Jun 1, 2026
Nuvation Bio Inc. (NASDAQ:NUVB) is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in New York, New York. Originally incorporated as RePharmation Inc., the company changed its name to Nuvation Bio Inc. in April 2019 and went public in August 2020. The company focuses on developing innovative therapeutic candidates for oncology, with its lead asset taletrectinib approaching FDA approval with a PDUFA date of June 23, 2025.
Similar companies
Latest newsMore news →
The U.S. Food and Drug Administration approved Nuvation Bio's supplemental New Drug Application for IBTROZI (taletrectinib) for locally advanced or metastatic ROS1-positive non-small cell lung cancer, updating the duration of response in TKI-naïve patients.33d agoNuvation Bio announced new subgroup analyses from the pivotal TRUST-I and TRUST-II studies showing durable, consistent efficacy of IBTROZI (taletrectinib) across key patient subgroups in advanced ROS1+ NSCLC at the 2026 World Conference on Lung Cancer.35d agoNuvation Bio Inc. issued $250.0 million aggregate principal amount of 0.75% Convertible Senior Notes due 2032, with an option for underwriters to purchase an additional $37.5 million, generating approximately $241.2 million in net proceeds (approximately $277.6 million if the overallotment option is fully exercised).112d ago